Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Live Chat available weekdays, 7:00 am - 6:30 pm CT
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Neuroblastoma is the most common cancer in infants and most often occurs in children under the age of 5. While there are a few known genetic factors that increase the risk of neuroblastoma, the cause of most neuroblastomas is not known.
Scientists have found some risk factors, but most children with neuroblastoma do not have any known risk factors. A risk factor is anything that affects a person’s chance of getting a disease such as cancer.
Nerve cells and cells in the medulla (center) of the adrenal gland start out as neuroblasts in a growing fetus. Most often, neuroblasts grow and develop into mature cells. Neuroblastomas can occur when normal fetal neuroblasts do not mature but instead continue to grow and divide.
Some neuroblasts might not have matured completely by the time a baby is born. Most of these eventually mature into normal nerve cells over time, or they simply die off and do not form cancer.
But sometimes, neuroblasts do not mature and continue to grow, forming a tumor. Many of these tumors will still eventually mature into nerve tissue or go away on their own. But as children get older, it becomes less likely that these cells will mature, and more likely that they will grow into cancer.
The reason some neuroblasts do not mature is because they have changes in their DNA. DNA is the chemical in each of our cells that makes up our genes. Genes control how our cells function. Changes (mutations) in the DNA inside our cells can sometimes change the way some genes work, which can promote cancer growth.
Some genes control when our cells grow, divide into new cells, and die:
Neuroblastoma cells can have chromosome changes (such as having too many or too few chromosomes, or missing part of a chromosome) that affect certain genes. Scientists are still trying to determine which genes are affected by these chromosome changes, and how these changes affect the growth of neuroblastoma.
Most neuroblastomas are the result of gene changes in neuroblasts that happen during the child’s development, sometimes even before birth. The cause of these acquired (somatic) gene changes is not known.
These acquired gene changes are found only in the child’s cancer cells, so they will not be passed on to their children.
In rare cases, neuroblastoma occurs because of gene changes inherited from a parent. Inherited (germline) changes in certain genes account for most hereditary (familial) neuroblastomas:
It is still not clear what causes many of the gene and chromosome changes that can lead to neuroblastoma. There are no clear lifestyle-related or environmental causes of neuroblastomas. Researchers have not found anything that can be done to prevent these cancers.
A risk factor is anything that increases the chances of getting a disease such as cancer. Different types of cancer have different risk factors.
Neuroblastoma is most common in infants and very young children. It is very rare in people over the age of 10 years.
Most children with neuroblastoma do not have a family history of neuroblastoma. Family history is only identified in 1-2% of children with neuroblastoma.
In children with a familial form of neuroblastoma (those with an inherited tendency to develop this cancer), the average age at diagnosis is younger than the age for sporadic (not inherited) cases. Children with familial neuroblastoma sometimes develop more than one of these cancers, often in different organs (for example, in both adrenal glands or in more than one sympathetic ganglion).
It is important to know if neuroblastoma started in more than one organ or if it started in one organ and then spread to others (called metastatic neuroblastoma). Tumors that develop in several places at once are more likely to be familial. Children with a family history of neuroblastoma or who have more than one neuroblastoma tumor may be recommended to have genetic counseling and testing (see Genetic Testing: What You Need to Know).
Genes and conditions associated with familial neuroblastoma include:
Experts may recommend screening for neuroblastoma in higher risk children when they are young.
Some studies have shown that children with certain birth defects might have an increased risk of developing neuroblastoma. The link between some birth defects and neuroblastoma might be related to changes in genes that happen during fetal development.
Genes are instructions in each of our cells that tell them what to do. The development of a fetus, which happens in a mother's womb, is controlled by genes that tell the cells how to grow and divide. If cell growth and development does not happen normally in the fetus, it can lead to a birth defect. Changes in genes during fetal development might also increase the risk of some childhood cancers, like neuroblastoma.
Currently, there are no known ways to prevent most cancers in children.
The known risk factors for neuroblastoma cannot be changed. Some studies suggest prenatal multi-vitamins or folic acid during pregnancy might lower the risk of neuroblastoma. Further research is needed.
If there is a history of neuroblastoma in your family, you may want to talk with a genetic counselor about your child’s risk of developing the disease. It is important to remember, though, that familial neuroblastoma is very rare.
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Dome JS, Rodriguez-Galindo C, Spunt SL, Santana VM. Chapter 92: Pediatric solid tumors. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, PA. Elsevier; 2020.
Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of pediatric cancers: A meta-analysis. Clin Pharmacol Ther. 2007;81:685–691.
Graham Fisher P, Reynolds P, Von Behren J, et al. Cancer in children with nonchromosomal birth defects. J Pediatr. 2012; 160: 978-983.
National Cancer Institute. Neuroblastoma Treatment (PDQ). 2024. Accessed at https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq on March 24, 2025.
Park JR, Hogarty MD, Bagatell R, et al. Chapter 23: Neuroblastoma. In: Blaney SM, Adamson PC, Helman LJ, eds. Pizzo and Poplack’s Principles and Practice of Pediatric Oncology. 8th ed. Philadelphia Pa: Lippincott Williams & Wilkins; 2021.
Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015: 30;3008-3017.
Shohet JM, Nuchtern JG. Epidemiology, pathogenesis, and pathology of neuroblastoma. UpToDate. 2025. Accessed at https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-neuroblastoma on March 24, 2025.
Last Revised: June 26, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.